Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

December 16, 2020

Primary Completion Date

July 19, 2023

Study Completion Date

August 31, 2027

Conditions
Congenital Adrenal Hyperplasia
Interventions
DRUG

Crinecerfont

CRF type 1 receptor antagonist

DRUG

Placebo

Non-active dosage form

Trial Locations (70)

1070

Neurocrine Clinical Site, Brussels

1090

Neurocrine Clinical Site, Vienna

1431

Neurocrine Clinical Site, Sofia

1606

Neurocrine Clinical Site, Sofia

2333

Neurocrine Clinical Site, Leiden

3000

Neurocrine Clinical Site, Leuven

8036

Neurocrine Clinical Site, Graz

10029

Neurocrine Clinical Site, New York

11000

Neurocrine Clinical Site, Belgrade

11021

Neurocrine Clinical Site, Great Neck

11527

Neurocrine Clinical Site, Athens

15224

Neurocrine Clinical Site, Pittsburgh

17176

Neurocrine Clinical Site, Stockholm

19104

Neurocrine Clinical Site, Philadelphia

20132

Neurocrine Clinical Site, Milan

20149

Neurocrine Clinical Site, Milan

20982

Neurocrine Clinical Site, Bethesda

27157

Neurocrine Clinical Site, Winston-Salem

28034

Neurocrine Clinical Site, Madrid

30329

Neurocrine Clinical Site, Atlanta

35128

Neurocrine Clinical Site, Padua

38700

Neurocrine Clinical Site, Grenoble

40138

Neurocrine Clinical Site, Bologna

41013

Neurocrine Clinical Site, Seville

41345

Neurocrine Clinical Site, Gothenburg

44093

Neurocrine Clinical Site, Nantes

45147

Neurocrine Clinical Site, Essen

46202

Neurocrine Clinical Site, Indianapolis

48109

Neurocrine Clinical Site, Ann Arbor

49933

Neurocrine Clinical Site, Angers

50005

Neurocrine Clinical Site, Hradec Králové

50139

Neurocrine Clinical Site, Florence

54642

Neurocrine Clinical Site, Thessaloniki

55454

Neurocrine Clinical Site, Minneapolis

55905

Neurocrine Clinical Site, Rochester

60126

Neurocrine Clinical Site, Ancona

60590

Neurocrine Clinical Site, Frankfurt

63110

Neurocrine Clinical Site, St Louis

64239

Neurocrine Clinical Site, Tel Aviv

74135

Neurocrine Clinical Site, Tulsa

75390

Neurocrine Clinical Site, Dallas

75651

Neurocrine Clinical Site, Paris

75679

Neurocrine Clinical Site, Paris

80045

Neurocrine Clinical Site, Aurora

80131

Neurocrine Clinical Site, Naples

80336

Neurocrine Clinical Site, Munich

90027

Neurocrine Clinical Site, Los Angeles

92123

Neurocrine Clinical Site, San Diego

94143

Neurocrine Clinical Site, San Francisco

94270

Neurocrine Clinical Site, Le Kremlin-Bicêtre

98105

Neurocrine Clinical Site, Seattle

98125

Neurocrine Clinical Site, Messina

1834111

Neurocrine Clinical Site, Afula

4941480

Neurocrine Clinical Site, Petah Tikva

8410101

Neurocrine Clinical Site, Beersheba

02115

Neurocrine Clinical Site, Boston

B3H 2Y9

Neurocrine Clinical Site, Halifax

01307

Neurocrine Clinical Site, Dresden

04103

Neurocrine Clinical Site, Leipzig

106 76

Neurocrine Clinical Site, Athens

115 27

Neurocrine Clinical Site, Athens

00161

Neurocrine Clinical Site, Roma

31-011

Neurocrine Clinical Site, Krakow

60-355

Neurocrine Clinical Site, Poznan

01-809

Neurocrine Clinical Site, Warsaw

4200-319

Neurocrine Clinical Site, Porto

CF14 4HH

Neurocrine Clinical Site, Cardiff

WC1B 5EH

Neurocrine Clinical Site, London

M20 4BX

Neurocrine Clinical Site, Manchester

M6 8HD

Neurocrine Clinical Site, Salford

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY